BACKGROUND: Most deaths in the 1918 influenza pandemic were caused by secondary bacterial pneumonia. METHODS: We performed a systematic review and reanalysis of studies of bacterial vaccine efficacy (VE) in preventing pneumonia and mortality among patients with influenza during the 1918 pandemic. RESULTS: A meta-analysis of 6 civilian studies of mixed killed bacterial vaccines containing pneumococci identified significant heterogeneity among studies and estimated VE at 34% (95% confidence interval [CI], 19%-47%) in preventing pneumonia and 42% (95% CI, 18%-59%) in reducing case fatality rates among patients with influenza, using random-effects models. Using fixed-effect models, the pooled VE from 3 military studies was 59% (95% CI, 43%-70%) for pneumonia and 70% (95% CI, 50%-82%) for case fatality. Military studies showed less heterogeneity and may provide more accurate results than civilian studies, given the potential biases in the included studies. Findings of 1 military study using hemolytic streptococci also suggested that there was significant protection. CONCLUSIONS: Despite significant methodological problems, the systematic biases in these studies do not exclude the possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to multiple pneumococcal serotypes and that bacterial vaccines may play a role in preventing influenza-associated pneumonia.
BACKGROUND: Most deaths in the 1918 influenza pandemic were caused by secondary bacterial pneumonia. METHODS: We performed a systematic review and reanalysis of studies of bacterial vaccine efficacy (VE) in preventing pneumonia and mortality among patients with influenza during the 1918 pandemic. RESULTS: A meta-analysis of 6 civilian studies of mixed killed bacterial vaccines containing pneumococci identified significant heterogeneity among studies and estimated VE at 34% (95% confidence interval [CI], 19%-47%) in preventing pneumonia and 42% (95% CI, 18%-59%) in reducing case fatality rates among patients with influenza, using random-effects models. Using fixed-effect models, the pooled VE from 3 military studies was 59% (95% CI, 43%-70%) for pneumonia and 70% (95% CI, 50%-82%) for case fatality. Military studies showed less heterogeneity and may provide more accurate results than civilian studies, given the potential biases in the included studies. Findings of 1 military study using hemolytic streptococci also suggested that there was significant protection. CONCLUSIONS: Despite significant methodological problems, the systematic biases in these studies do not exclude the possibilities that whole-cell inactivated pneumococcal vaccines may confer cross-protection to multiple pneumococcal serotypes and that bacterial vaccines may play a role in preventing influenza-associated pneumonia.
Authors: Richard Malley; Sarah C Morse; Luciana C C Leite; Ana Paula Mattos Areas; Paulo Lee Ho; Flavia S Kubrusly; Igor C Almeida; Porter Anderson Journal: Infect Immun Date: 2004-07 Impact factor: 3.441
Authors: R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson Journal: Infect Immun Date: 2001-08 Impact factor: 3.441
Authors: Thais Mauad; Ludhmila A Hajjar; Giovanna D Callegari; Luiz F F da Silva; Denise Schout; Filomena R B G Galas; Venancio A F Alves; Denise M A C Malheiros; Jose O C Auler; Aurea F Ferreira; Marcela R L Borsato; Stephania M Bezerra; Paulo S Gutierrez; Elia T E G Caldini; Carlos A Pasqualucci; Marisa Dolhnikoff; Paulo H N Saldiva Journal: Am J Respir Crit Care Med Date: 2009-10-29 Impact factor: 21.405
Authors: J F Brundage; J D Gunzenhauser; J N Longfield; M V Rubertone; S L Ludwig; F A Rubin; E L Kaplan Journal: Pediatrics Date: 1996-06 Impact factor: 7.124
Authors: Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber Journal: Vaccine Date: 2011-04-08 Impact factor: 3.641
Authors: Joshua M Klonoski; Heather R Hurtig; Brian A Juber; Margaret J Schuneman; Thomas E Bickett; Joshua M Svendsen; Brandon Burum; Thomas A Penfound; Grigoriy Sereda; James B Dale; Michael S Chaussee; Victor C Huber Journal: Vaccine Date: 2014-07-29 Impact factor: 3.641